(NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialisation of Locilex
(pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, which recently announced that Locilex
failed to meet the primary and secondary endpoints in its OneStep-1 and OneStep-2 Phase 3 clinical trials.
M2 PHARMA-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
M2 PHARMA-July 23, 2014-Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
Dipexium recently completed its pivotal Phase 3 clinical trials (OneStep-1 and OneStep-2) with Locilex
in mild infections of diabetic foot ulcers in the United States under a Special Protocol Assessment (SPA) agreement from the US Food and Drug Administration (FDA).
M2 EQUITYBITES-February 5, 2016-Dipexium Pharmaceuticals completes 75% enrollment under Pivotal Phase 3 clinical trials of Locilex
M2 EQUITYBITES-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex